Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Union Budget
Budget 2011-2012 Home
Industry Expectations - Budget 2011-2012
Industry Reactions - Budget 2011-2012
Budget 2010-2011
Budget 2010-2011 Home
Industry Expectations - Budget 2010-2011
Industry Reactions - Budget 2010-2011
Contributor's Corner
Bonanza Portfolio
Hemant K Gupta
Krish Bhatt
S A A R T H I
Trinity Investments
Exchange Information
BSE 2009 Holidays
NSE 2009 Holidays
Investor Guide
Depository & Dematerialisation
Grievance Redressal
Investor Guide
SEBI
Trading of Securities
Transfer of Securities
Your Rights
Budget 2009-2010
Budget 2009-2010 Home
Industry Expectations - Budget 2009-2010
Industry Reactions - Budget 2009-2010
Interim Budget 2009-2010 Home
Industry Expectations - Interim Budget 2009
Budget 2008-2009
Railway Budget 2008-2009
Industry Expectations - Budget 2008
Union Budget 2008-2009
Highlights of Budget 2008-2009
Summary of Budget 2008-2009
Industry Reactions - Budget 2008
IPOs
Current IPOs
Past IPOs
IPO Subscription
Mutual Funds
Gold Exchange Traded Fund
MF Unique Holding
Forthcoming Dividends
ELSS Schemes Comparison
Tax Plans
New Fund Offers
Research
Arbitrages
Equity
Market Whispers
Tax Planning
Home
Equity Linked Savings Scheme
Post Office MIS
9% GOI Senior Citizens Savings Scheme
8% Savings (Taxable) Bonds
Kisan Vikas Patra
National Savings Certificate
Public Provident Fund
Research

| More

Colgate Palmolive (India) - 1QFY17 Result Update - Volumes Recover but at a Cost - Reliance Securities

Posted On: 2016-08-15 20:08:53

Net sales of Colgate Palmolive (India) grew 8.9% yoy to Rs10.1bn, while EBITDA growth was recorded at 3.6% and PBT (before exceptional items) increased by just 1.7% to Rs1.9bn in the quarter ended June 30, 2016. It reported overall volume growth of 6% with domestic volume growing by 5%. While gross sales growth was higher at 12.5%, net sales grew just 8.9% on account of sharp 49% jump in tax outgo resulting from phasing out of Excise Duties benefits.

Going forward, we estimate the volume growth to pick up pace, especially with the launch of Cibaca Vedshakti in the naturals space at an attractive price point. However, this is likely to keep A&P spends at elevated levels, which would drag earnings growth, in our view. We expect the Company to report 12.7% and 10% CAGR in revenues and earnings through FY16-18E. We reiterate our HOLD recommendation on the stock with revised Target Price of Rs1,055.

Volumes Recovery in Process

Domestic business witnessed 5% volume growth during the quarter. Although, the Company has lost market share on yoy basis, it has recovered some share sequentially. Volume-wise, market share in toothpaste stood at 55.9% in June'16 vs. 55.3% in Mar'16 and 57.9% in 1HCY15. On the other hand, volume market share in Toothbrush was higher both on yoy as well as qoq basis. It stood at 46.8% in June'16 vs. 45.8% in Mar'16 and 42.7% in 1HCY15. The Company stated that new products such as Colgate Sensitive Clove & Colgate A1 Toothbrush led overall growth in the quarter.

Higher A&P Spend Drags EBITDA Margins

Weak demand environment and heightened competitive intensity resulted in 190bps rise in A&P spends to 15.5% of sales. With launch of Cibaca Vedshakti at 30% discount to effectively counter Patanjali Dant Kanti, we expect A&P spends to remain at elevated levels, going forward. Although gross margins were higher by 140bps, higher A&P and staff cost dragged EBITDA margins by 100bps to 20.3% during the quarter.

Outlook & Valuation

We expect Colgate to post revenues of Rs46.4bn & Rs52.4bn and net profit of Rs6.4bn & Rs7.3bn in FY17E & FY18E respectively. Based on expected EPS of Rs27, currently the stock trades at 37.7x FY18E earnings. While we expect volume growth and market shares to recover, higher A&P spends could cap earnings growth in coming quarters. We retain our HOLD rating on the stock with revised Target Price of Rs1,055, based on 38x June'16 earnings, which is a 10% discount to its average one-year forward multiple.

Shares of COLGATE-PALMOLIVE (INDIA) LTD. was last trading in BSE at Rs.956 as compared to the previous close of Rs. 960.95. The total number of shares traded during the day was 21150 in over 918 trades.

The stock hit an intraday high of Rs. 970.5 and intraday low of 951. The net turnover during the day was Rs. 20342655.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com


Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only. www.equitybulls.com, its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. www.equitybulls.com or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.





Other Headlines:

Views on Axis Banks Ltd 3QFY2017 Results: Angel Broking
Views on Yes Bank Limited 3QFY2017 Results: Angel Broking
Power Sector - Results Preview - Higher Fuel Cost & Muted Demand Growth to Impact Profitability - Reliance Securities
DCB Bank - 3QFY17 Result Update -BUY- Strong Core Earnings, Stable Asset Quality - Reliance Securities
Housing Finance Companies with retail focus will continue to see strong growth: Angel Broking
Pharmaceutical - Results Preview - Mixed Performance in the US Biz; Domestic Biz to See Moderate Growth - Reliance Securities
Cyient - Result Update - BUY- Soft as Expected, Order Book Healthy - Reliance Securities
TCS - 3QFY17 Result Update - REDUCE - Good Quarter, but Top-level Rejig a Headwind - Reliance Securities
Views on Infosys Ltd 3QFY2017 Results: Angel Broking
Bajaj Corp - Result Update - BUY - Decent Performance; Recovery in Sight - Reliance Securities
Infosys - 3QFY17 Result Update - BUY - Encouraging Performance, BFSI Strength Enthuses - Reliance Securities
Views on Tata Consultancy Services Limited 3QFY2017 Results: Angel Broking
CPSE ETF Note - Further Fund Offer of CPSE ETF - Reliance Securities
Capital Goods - Thematic Report - Imminent Capex Visibility in T&D Space to Aid Key Segmental Players - Reliance Securities
FMCG - Results Preview - Demonetisation Steals the Show...Literally! - Reliance Securities
IndusInd Bank - Result Update - BUY - Stellar Performance Continues ... Reiterate BUY - Reliance Securities
Cement Monthly Sector Update - Realizations Softened on Insipid Demand - Reliance Securities
Jubilant FoodWorks - Initiating Coverage - BUY Risk Reward Ratio Turning Favourable despite Near-term Uncertainties - Reliance Securities
Cyient - Initiating Coverage - BUY - Engineered for Growth - Reliance Securities
Aurobindo Pharma - Event Update - BUY - Generis acquisition to boost margin - Reliance Securities
Initiating Coverage - KEI Industries: Angel Broking
L&T Construction Wins Orders Valued Rs. 3039 Crores
TCS (TCS IN) - Revenue growth way below street expectation - Cholamandalam Securities
Infosys (INFO IN) - Result in-line with street expectation; guidance disappoints - Cholamandalam Securities
BUY Dishman Pharma - Better traction expected from CRAMS and disinfectants: AnandRathi Institutional Research
Neutral on ICICI Prudential Life Insurance Co. Ltd. IPO - Angel Broking
ICICI Prudential Life Insurance Company Ltd - IPO Note - Religare
ICICI Prudential Life Insurance Co. Ltd. - Pure play on life insurance - Geojit BNP Paribas
Fiberweb India Ltd - Set to grow at a rapid pace; initiate with BUY - BOB Capital Markets Ltd
BUY Bajaj Electricals - Growth momentum in all divisions expected in 2HFY17: AnandRathi Institutional Equity
Majesco Ltd - Well-placed to Leverage Conducive Industry Tailwinds - Reliance Securities
HCL Technologies - Event Update - Automation Focus a Key Differentiator - Reliance Securities
Aurobindo Pharma - 1QFY2017 Result Update - Angel Broking
HOLD India Cements - Subdued quarter; prices to recover: AnandRathi Institutional Research
Cement - 1QFY17 Results Review - Robust performance continues on cost benefits - Reliance Securities
NTPC 1QFY17: Result Review - In line with our expectations - Maintain BUY - Reliance Securities
KNR Constructions - 1QFY2017 Result Update - Angel Broking
BUY NRB Bearings - Margin expansion in Q1 leads to robust profitability: AnandRathi Institutional Reserach
BUY AIA Engineering - Margins likely to hold: AnandRathi Institutional Reserach
BUY Vivimed Labs - Better pharma growth, lower interest cost drive earning - Anand Rathi
Radico Khaitan - 1QFY2017 Result Update - Angel Broking
BUY KNR Constructions - Strong beginning, move toward a high-growth trajectory; AnandRathi Institutional Research
Dishman Pharmaceuticals - 1QFY2017 Result Update - Angel Broking
BUY Ahluwalia Contracts India - Steady growth intact: AnandRathi Institutional Research
BUY JK Lakshmi Cement - Strong start; growth set to endure: AnandRathi Institutional Research
Ahluwalia Contracts India Ltd - 1QFY17 Result Update - BUY - Healthy Performance Continues - Reliance Securities
Sun Pharmaceuticals - 1QFY2017 Result Update - Angel Broking
BUY MRF - Outstripping yet again: Anand Rathi Institutional Research
Bajaj Electricals - 1QFY2017 Result Update - Angel Broking
Lupin - 1QFY2017 Result Update - Angel Broking


Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2016